Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2015–2018

HyMedPoly · Drug-Free Antibacterial Hybrid Biopolymers for Medical Applications

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-01-01 → 2018-12-31
Финансиране от ЕС
3 918 055 €
Участници
8
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Хибридни биополимери без лекарства, като композити със стъкло и керамика, се разработват за борба с бактериалните инфекции. Те са важни, защото бактериите стават все по-устойчиви на антибиотици, което налага създаването на нови терапевтични материали за медицината.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Drug-Free Antibacterial Hybrid Biopolymers for Medical Applications

Infection has become one of the toughest problems in the medical world as bacteria become more resistant to drugs there are fewer effective antibiotics to fight against pathogens. The Marie Skłodowska Curie Innovative Training Network “Drug-Free Antibacterial Hybrid Biopolymers for Medical Applications”, HyMedPoly, focused on the production of drug-free antibacterial hybrid biopolymers as therapeutic materials to prevent, control and remove such occurrences. A cohort of fifteen Early Stage Researchers (ESRs) recruited specifically for the HyMedPoly programme has addressed new strategies to develop and establish new therapies based on intrinsically antibacterial polymers, polymers with antibacterial additives and polymer composites incorporating antibacterial glasses and ceramics. The HyMedPoly team of four universities, four companies, one clinic and one research organisation collaborated for four years to: - Validate the new materials concepts and determine key design parameters that will guide the development of families of novel therapeutic hybrid polymers to combat bacteria-related infection. - Evaluate industrial processing techniques to fabricate the medical materials and product demonstrators. - Provide a comprehensive and innovative training programme to meet industrial demands for fully rounded professional researchers. Our ultimate goal was to develop a new generation of professionals to play a pivotal role in pushing forward this challenging and knowledge-intensive field for the coming decades to benefit the European economy and who will be able to bring state-of-the-art technology to industry, advance products for hospitals and personal healthcare, and develop new and improved therapeutic strategies. At HyMedPoly’s conclusion in December 2018, novel biomaterials with improved antibacterial efficacy and novel processes had been developed and used to make prototype medical product demonstrators. Furthermore all researchers were on track to complete their PhDs with the first researcher awarded her degree.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

There is a general consensus that biomedical polymers of natural and synthetic origin should and will play a very important role in the development of new therapeutic strategies to treat diseases. Due to resistance of bacteria to drugs, infection has become one of the toughest problems in the medical world as there are hardly any effective antibiotics left in the fight against many pathogens. This project aims to develop new therapies through a new combination of technology (a) development of new hybrid polymers with antibacterial functionality,(b) introduction of inhibitors that can permanently deactivate bacteriological proteases and (c) new formulations of bioactive ceramics and glasses that have specific charge potential to prevent bacterial growth. The challenge is to develop new medical polymers that have an intrinsic antibacterial functionality to achieve clinical effectiveness in the field. To develop the challenge to practical medical solutions, a new generation of industrial professionals is needed. They should have a solid multidisciplinary background complemented by the required academic and industrial experiences. The objective of this network is to train young PhD researchers to fill this demand in the strategic area of drug-free antibacterial hybrid biomedical polymers. This EID programme will achieve this by a joint training programme of world class academic and industrial institutes who will provide hands-on training in state of the art research projects related to key fundamental issues that determine the future new therapies of antibacterial biomaterials. The goal is to develop professionals that will play a pivotal role in pushing forward this challenging and knowledge-intense field for the coming decades to benefit the European economy, bring state-of-the-art technology to industry with advanced products for hospitals and personal health care and contribute to the development of therapeutic strategies to improve the quality of life.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз